Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
OncoResponse logo — Interrogating for Cures

OncoResponse

Interrogating for Cures

Founded 2016 United States Houston, United States 10 employees Total: $117.10M Biopharma, Biotechnology +2

General Information

Company Name OncoResponse
Founded Year 2016
Location United States Houston, United States
Founders / Decision Makers
Team member Team member
Employees 10
Industries Biopharma, Biotechnology, Health Care +1
Business Model B2B, B2D, Platform
Revenue Model Licensing, Performance Based, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with OncoResponse. To contact OncoResponse, visit oncoresponse.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does OncoResponse compare?

A PDF of OncoResponse and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting OncoResponse soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About OncoResponse

OncoResponse, founded in 2016, is an innovative player in the immuno-oncology biotech sector. This biopharma company is particularly notable for its strategic collaboration with the MD Anderson Cancer Center, which amplifies its capabilities in treating cancer.

Utilizing a proprietary B-cell discovery platform, OncoResponse is adept at developing novel therapeutics designed to target the tumor microenvironment. Their lead candidate, OR2805, is progressing through clinical trials, presenting a transformative approach to cancer treatment. This progress positions the company as a potential game-changer in advancing cancer therapeutics.

Headquartered in both Houston, Texas and Seattle, Washington, OncoResponse attracts significant attention from major investors. Its latest funding of $14.00 million in May 2023, secured from a consortium of respected investors, such as Arch Venture Partners and Takeda Ventures, enhances its financial runway to continue groundbreaking innovation in United States-based research.

Business keywords: Immuno-oncology, Biotech, Cancer immunotherapy, Antibody platform, B-cell discovery, Tumor microenvironment, Monoclonal antibodies, Immune activation, TME immunosuppression, Elite cancer responders, Novel therapeutics, Myeloid biology, Clinical trials, Human antibodies

Services & Products

Development of novel cancer immunotherapies
Discovery of human antibodies
Partnering with collaborators in immuno-oncology
Preclinical studies

Target Customers

Biopharmaceutical companies Oncology researchers Cancer patients Clinical study collaborators

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Grant $14.00M 7
Arch Venture Partners RiverVest 3B Future Health Fund
Arch Venture Partners, RiverVest +5
01 May 2023
Spinout $40.60M 7
Arch Venture Partners Qatar Investment Authority Redmile Group
Arch Venture Partners, Qatar Investment Authority +5
01 Mar 2021
Series B $40.00M 7
Arch Venture Partners RiverVest Qatar Investment Authority
Arch Venture Partners, RiverVest +5
01 Sep 2018
Series A $3.00M -
01 Mar 2017
Series A $7.00M 2
GreatPoint Ventures 3B Future Health Fund
GreatPoint Ventures, 3B Future Health Fund
01 Oct 2016
Series A $12.50M 6
GreatPoint Ventures Arch Venture Partners 3B Future Health Fund
GreatPoint Ventures, Arch Venture Partners +4
01 May 2016

OncoResponse Alternatives & Competitors

View All Alternatives
OncoResponse vs
Surface Oncology Inc.
Surface Oncology Inc. United States

#lifeunderthesurface #BBJBestPlacesToWork2023,2022,2021 #BostonGlobeTopPlacesToWork2023,2022,2021

Post-IPO Equity
14 employees
Biotechnology, Health Care
OncoResponse vs
NextPoint Therapeutics, Inc.
NextPoint Therapeutics, Inc.

Launching a new world of precision therapeutics through its leading scientific work on the novel B7...

38 employees
Biotechnology, Health Care
Compare OncoResponse vs NextPoint Therapeutics, Inc.
OncoResponse vs
FogPharma
FogPharma United States

Until everything is druggable.

Series E
146 employees
Biopharma, Biotechnology
Compare OncoResponse vs FogPharma
View all alternatives

FAQ About OncoResponse

Interrogating for Cures
OncoResponse was founded in 2016.
OncoResponse is headquartered in Houston, United States.
OncoResponse operates in Biopharma, Biotechnology, Health Care and Health and Wellness. Its work centres on Immuno-oncology, Biotech, Cancer immunotherapy and Antibody platform. Its customers include Biopharmaceutical companies, Oncology researchers and Cancer patients.
OncoResponse has a B2B, B2D and Platform business model. Its revenue comes from Licensing, Performance Based and Service Fee.
OncoResponse has approximately 10 employees.
OncoResponse has completed 6 funding rounds, raising a total of $117.10M.
OncoResponse offers: Development of novel cancer immunotherapies, Discovery of human antibodies, Partnering with collaborators in immuno-oncology, Preclinical studies.
Top alternatives and competitors to OncoResponse include Surface Oncology Inc., NextPoint Therapeutics, Inc., FogPharma, Aulos Bioscience, Oxford BioTherapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
OncoResponse and Surface Oncology Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for OncoResponse, https://bouncewatch.com/company/oncoresponse, updated 9 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes